Review Article

Comparison of Patient Outcomes following Implantation of Trifocal and Extended Depth of Focus Intraocular Lenses: A Systematic Review and Meta-Analysis

Yining Guo,1,2 Yinhao Wang,1,2 Ran Hao,1,2 Xiaodan Jiang,1,2 Ziyuan Liu,1,2 and Xuemin Li1,2

1Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China
2Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Beijing 100191, China

Correspondence should be addressed to Xuemin Li; lxmlxm66@sina.com

Received 9 November 2021; Accepted 17 December 2021; Published 29 December 2021

Academic Editor: Alessandro Meduri

Copyright © 2021 Yining Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The purpose is to compare the outcomes of implantation of trifocal intraocular lenses (TIOLs) and extended depth of focus (EDOF) intraocular lenses (IOLs). Methods. A comprehensive search of PubMed, Cochrane Library, EMBASE, and ClinicalTrial.gov was conducted in March 2020 to identify relevant studies. A meta-analysis of the results was performed. Patients implanted with EDOF IOLs or TIOLs in previous studies were included. The primary outcomes of the study were uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), uncorrected near visual acuity (UNVA), and defocus curve. Results. TIOLs and EDOF IOLs provided comparable binocular UDVA (MD = -0.01, 95% CI: -0.04, 0.03, logMAR). However, EDOF IOLs provided better UIVA (MD: -0.08, 95% CI: -0.14, -0.01, logMAR) and worse UNVA (MD: 0.10, 95% CI: 0.06, 0.14, logMAR) than TIOLs. Fewer patients achieved spectacle independence after implantation of EDOF IOLs (RR: 0.74, 95% CI: 0.63, 0.87) than after implantation of TIOLs, especially for near vision (RR = 0.82, 95% CI: 0.68, 0.99). There was no statistically significant difference in contrast sensitivity (CS) under photopic or mesopic conditions with both IOLs. Patient satisfaction after implantation of both IOLs was high. Conclusion. EDOF IOLs and TIOLs provide comparable distance vision. However, EDOF IOLs provide better intermediate vision and worse near vision than TIOLs. The advantages of EDOF IOLs over TIOLs in terms of CS, aberrations, and visual disturbance are not significant. Patients are satisfied with both types of IOLs.

1. Introduction

Lens extraction combined with implantation of intraocular lenses (IOLs), which is an established and effective procedure, improves visual quality after cataract surgery [1–3]. Monofocal IOLs can provide excellent distance visual acuity [4]. However, patients can only see objects clearly around the area of focus, and spectacles are required for near and intermediate vision. With the increasing demand for spectacle independence, different presbyopia-correcting IOLs, such as multifocal IOLs (MIOLs), are recommended for better intermediate and near visual acuity [5–7].

MIOLs incorporate two or three foci through a diffractive or refractive design [8]. Patients implanted with MIOLs have better intermediate and near visual acuity and higher spectacle independence than those implanted with monofocal IOLs [2]. However, although patients implanted with MIOLs can see objects at different distances, they still cannot have satisfying visual quality between the separate foci [9]. Besides, the distribution of light in multiple focal points reduces postoperative contrast sensitivity (CS) and increases the incidence rate of disturbing photic phenomena such as halos and glare [10, 11]. To combat this problem, extended depth of focus (EDOF) IOLs were introduced. They were designed to provide good vision across a
continuous range of foci and decrease the rate of visual disturbances [12–14].

The design pattern of EDOF IOLs elongates the depth of focus from intermediate to far distances and forms a continuum of foci [15, 16]. There are several types of EDOF IOLs, including IOLs based on diffractive optics, nondiffractive optics, small aperture, and bioanalogic designs [16]. TECNIS Symfony, the most widely used type of EDOF IOL in clinical practice, is an example of a diffractive hydrophobic EDOF IOL that has an achrrotic pattern, which can compensate for corneal chromatic aberration [12, 14–16]. Previous studies have demonstrated that the TECNIS Symfony IOL showed great safety with low rates of posterior capsule opacification (PCO) and adverse events [17, 18]. As this type of IOL has an aspheric anterior surface and a continuum of foci instead of separate foci, they are expected to decrease the incidence of pheno mimics such as halos [14]. Thus, EDOF IOLs are considered to bridge the gap between MIOLs and monofocal IOLs [16].

Although the original concept of the EDOF design shows great advantages, the specific clinical effect of this new type of IOL is still not very clear. Whether it can challenge the traditional MIOLs remains to be verified. Liu et al. conducted a meta-analysis to compare the implantation of TECNIS Symfony IOLs with the implantation of multifocal IOLs and trifocal IOLs (TIOLs); however, only six studies that compared Symfony IOLs and TIOLs were included, and monocular uncorrected visual acuity, monocular and binocular corrected visual acuity, refraction, and aberrations were not compared in their analysis [11]. After that meta-analysis was conducted, a lot of original studies that compared TECNIS Symfony IOLs and TIOLs were conducted. The purpose of the present study was to meta-analyze the results of these original studies and provide more evidence for comparing TECNIS Symfony IOLs and TIOLs from multiple perspectives.

2. Methods

2.1. Search Strategy. This systematic review and meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses Statement [19]. The protocol for this meta-analysis is registered with PROSPERO (CRD42020187618). PubMed, Cochrane Library, EMBASE, and ClinicalTrial.gov, were searched for relevant controlled studies published from January 2000 to March 2020. No language restrictions were applied. The following terms were used to search the databases: “extended depth of focus,” “extended range of vision,” “EDOF,” “Lenses, intraocular” [Mesh], “Intraocular lens,” “Intraocular lenses,” “Lens, Intraocular,” “Implantable Contact Lens,” “Contact Lens, Implantable,” “Lens, Implantable Contact,” “Lens implantation, intraocular” [Mesh], “Implantation, Intraocular Lens,” “Implantations, Intraocular Lens,” “Intraocular Lens Implantation,” “Intraocular Lens Implantations,” and “Lens Implantations, Intraocular.” The reference lists of key articles and relevant systematic reviews were searched manually to identify other potentially relevant studies. Two reviewers (Y. G. and Y. W.) conducted the search independently; a third reviewer (X. J.) was consulted in cases of disagreement.

2.2. Eligibility Criteria and Outcomes. All randomized controlled trials (RCTs) and nonrandomized controlled studies (NRCSs) that compared implantation of EDOF IOLs and TIOLs after cataract surgery were selected. Ongoing studies and studies on binocular blended implantation were excluded. Monocular and binocular uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), uncorrected near visual acuity (UNVA), and defocus curves were defined as primary outcomes. Different defocus levels were introduced, from +1.00 to −4.00 diopters (D), in 0.50 D steps. Secondary outcomes included monocular and binocular corrected distance visual acuity (CDVA), distance corrected intermediate visual acuity (DCIVA), distance-corrected near visual acuity (DCNVA), refraction (including spherical equivalent refractive error, residual sphere, and residual astigmatism), spectacle independence, CS, aberrations, quality of vision and patient satisfaction, complications, and adverse events.

2.3. Risk of Bias Assessment and Data Extraction. The quality of RCTs was assessed using the Cochrane Collaboration Risk of Bias Tool [20]. Seven different aspects were evaluated according to the domains of the tool: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other potential bias. Regarding the level of risk of bias, each item was rated as having a “low risk,” “high risk,” or “unclear risk.”

The Newcastle-Ottawa Scale (NOS) was used to assess the risk of bias of NRCSs [21]. Three aspects were assessed, namely: the selection of groups, the comparability between patients in different treatment arms, and outcome assessment. To analyze and quantify the risk of bias using the NOS, a scale system is used. Each item can get at most one star in the “selection” and “outcome assessment” domains, and two stars at most in the “comparability” domain. The total number of stars ranges from 0 to 9; studies that score 0 to 3, 4 to 6, and 7 to 9 are considered low-, moderate-, and high-quality studies, respectively.

Two reviewers (Y. G. and Y. W.) independently extracted data from the included studies using a standard form. Discrepancies between the decisions of the two reviewers were resolved by consensus; a third reviewer (X. J.) was consulted when necessary. We extracted the characteristics of each study and details of the outcomes mentioned previously. For continuous variables, including visual acuity, defocus curves, refraction, and CS, we extracted the mean values and standard deviations (SD). For dichotomous variables, the number of events, such as spectacle independence, in each treatment group was extracted. For data that could not be merged, such as quality of vision and patient satisfaction, we only summarized and described the results. We contacted the authors of the studies for additional information by e-mail when necessary.
2.4. Data Synthesis and Statistical Analysis. The Review Manager 5.3 and Stata/SE 14.0 for Windows (StataCorp LP, USA) software programs were used to analyze the data. The Q test and I² statistic were used to assess heterogeneity, and I² > 50% was regarded as an indication of substantial heterogeneity [20]. If I² was above 50%, the random-effects model was used; otherwise, we utilized the fixed-effects model. Mean deviation (MD, mean value of EDOF IOLs minus mean value of TIOLs) with 95% confidence interval (CI) was calculated for the continuous variables except CS, and risk ratio (RR) or risk deviation (RD) with 95% CI was calculated for categorical variables. RD was chosen when the number of events equaled zero. For CS, various test tools and different expressions were used in the studies; thus, we used a standard mean deviation (SMD). P < 0.05 was considered statistically significant. The publication bias of each study was checked using funnel plots and Egger’s test. When a funnel plot asymmetry was noted, the trim-and-fill analysis was conducted to adjust the effect. Influence analysis was performed to verify the stability of the results.

For studies with two different TIOL implantation groups, the mean values and SDs for meta-analysis were combined according to formula (1) and formula (2), respectively. The total number of patients in the trifocal group is the sum of the two different trifocal groups. This data synthesis method was used by Cao et al. in a meta-analysis [2].

\[
\begin{align*}
\bar{x}_T &= \frac{n_1 \bar{x}_1 + n_2 \bar{x}_2}{n_1 + n_2}, \\
SD_T &= \sqrt{\frac{(n_1 - 1)SD_1^2 + (n_2 - 1)SD_2^2 + (n_1n_2/n_1 + n_2)(\bar{x}_1 - \bar{x}_2)^2}{n_1 + n_2 - 1}}.
\end{align*}
\]

3. Results

3.1. Search Results and Characteristics of the Included Studies. As shown in Figure 1, a total of 328 records were identified after searching. Twenty-one records were considered eligible after the initial screening. After further consideration, two articles were excluded because they were studies on blended implantation [22, 23], and four studies were excluded because their specific data were not available [24–27], and one study was excluded because it was an ongoing clinical trial [28]. After reading the full text, one study was excluded because its outcome could not be included in the analysis [29]. Finally, 13 studies (four RCTs [30–33] and nine NRCSs [18, 34–41]) were included in the analysis.

The characteristics of the included studies are summarized in Table 1. These studies were conducted in different countries. All studies were published between 2017 and 2020. A total of 1,221 eyes were included in the analysis. The TECNIS Symfony ZXR00 IOL was implanted in the eyes included in the EDOF group, whereas Acrysof IQ PanOptix, FineVision Micro F, FineVision Pod F, and AT LISA tri 839MP IOLs were implanted in the eyes included in the trifocal group. The parameters of these included IOLs are listed in Table S1. The follow-up duration of the studies ranged from 1 to 29 months.

3.2. Assessment of Risk of Bias. The risks of bias in the RCTs are shown in Figures 2 and 3. In Weber’s study, the randomization was disclosed at the three-month time point of the follow-up; this suggests the risk of detection bias. Details on allocation concealment were not clearly indicated in all studies, so the risk of bias is unclear in that regard. No other biases were found in all studies.

The qualities of the included NRCSs are shown in Table 2. Seven studies had 7–9 points, indicating that they are high-quality studies, whereas Rodov’s and Lin’s studies had 5 and 6 points, respectively, indicating that the studies are of moderate quality. Rodov’s study is a retrospective study, and there were significant differences in parameters such as age and preoperative astigmatism in different groups. In Lin’s study, no baseline information, such as patient age, was provided, and no long-term follow-up was conducted. Most studies had a sufficiently long follow-up period, and there was no significant difference in the baseline information of patients in different groups.

3.3. Primary Outcomes

3.3.1. Monocular and Binocular Uncorrected Visual Acuity. Visual acuity was reported in decimal format in two studies [30, 38]; we contacted the corresponding authors of the articles and received no responses. Therefore, data on uncorrected visual acuity were extracted from only 10 studies. Data on monocular uncorrected visual acuity were available in four studies, which included 158 eyes (Figure 4). There was no significant difference in monocular UDVA and UIVA between groups. Monocular UNVA was significantly worse in the EDOF group (MD: 0.14, 95% CI: 0.05 to 0.22, P = 0.002, logMAR) than in the trifocal group. Seven, five, and five studies reported binocular UDVA, UIVA, and UNVA, respectively (Figure 5). There was no significant difference in binocular UDVA between groups. EDOF IOLs provided better binocular UIVA (MD: -0.08, 95% CI: -0.14 to -0.01, P = 0.02, logMAR) but worse UNVA (MD: 0.10, 95% CI: 0.06 to 0.14, P < 0.0001, logMAR) than TIOLs. One study reported that binocular UNVA would be better if EDOF IOLs were targeted for micro-monovision (MD: 0.05, 95% CI: 0.00 to 0.10, P = 0.03, logMAR) [32].

3.3.2. Defocus Curves. Figure 6 shows the defocus curves derived from all the included studies. The MDs of visual acuity (logMAR) at different defocus levels in EDOF IOLs and TIOLs are listed in Table S2. Overall, the EDOF group had statistically significantly better intermediate visual acuity at -1D (1 m) (MD: -0.06, 95% CI: -0.10 to -0.05, P = 0.011) than the trifocal group, whereas the trifocal group performed significantly better at -2D to -4D (50 cm to 25 cm) than the EDOF group. A subgroup analysis was conducted based on study types (RCT or non-RCT). For non-RCTs, the EDOF group had statistically significantly
Records identified through database searching (n = 328, July 2005 to March 2020)
PubMed (n = 131)
EMBASE (n = 128)
The Cochrane library (n = 42)
ClinicalTrial.gov (n = 27)

Records after duplicates removed (n = 217)
165 records excluded after initial screening: Irrelevant studies (n = 94)
Non-comparative (n = 37)
in vitro studies (n = 23)
without trifocal intraocular lens (n = 30)

Records after initial screening (n = 33)
Clinical trials and conference abstracts with no results (n = 12)

Articles assessed for eligibility (n = 21)
Full-text articles excluded: blended implantation (n = 2)
Ongoing study (n = 1)
Unavailable data (n = 4)
Outcomes cannot be used (n = 1)

Studies included in analysis (n = 13)
RCTs (n = 4)
NRCSs (n = 9)

Figure 1: The flow diagram of identification and inclusion of the eligible studies based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses flowchart.

Table 1: Characteristics of the included studies (n = 13).

| Study | Location | Design | EDOF N (patients/eyes) | Age (mean ± SD, years) | IOL types | Trifocal N (patients/eyes) | Age (mean ± SD, years) | Follow-up duration (months) |
|-------|----------|--------|------------------------|------------------------|-----------|--------------------------|------------------------|-----------------------------|
| Monaco et al. 2017 [31] | Italy | RCT | TECNIS Symfony | 20/40 | 67.0 ± 8.5 | AcrySof IQ PanOptix FineVision Micro F | 20/40 | 66.0 ± 5.5 | 4 |
| Ruiz-Mesa et al. 2017 [18] | Spain | NRCS | TECNIS Symfony | 20/40 | 59.5 ± 8.9 | AcrySof IQ PanOptix FineVision Micro F | 20/40 | 54.5 ± 7.2 | 12 |
| Cochener et al. 2018 [30] | France | RCT | TECNIS Symfony | 20/40 | 69.2 ± 8.4 | AcrySof IQ PanOptix FineVision Micro F | 20/40 | 62.5 ± 4.6 | 6 |
| Mencucci et al. 2018 [34] | Italy | NRCS | TECNIS Symfony | 20/40 | 68.9 ± 4.8 | AcrySof IQ PanOptix AT LISA tri 839MP | 20/40 | 70.1 ± 4.8 | 3 |
| Ruiz-Mesa et al. 2018 [35] | Spain | NRCS | TECNIS Symfony | 14/28 | 63.1 ± 10.0 | AcrySof IQ PanOptix FineVision Micro F | 20/40 | 63.8 ± 8.1 | 9-29 |
| Escandon-Garcia et al. 2018 [36] | Portugal | NRCS | TECNIS Symfony | 15/30 | 63.5 ± 9.4 | AcrySof IQ PanOptix FineVision Pod F | 7/14 | 62.3 ± 9.0 | 1-3 |
better intermediate visual acuity from −0.5D to -1.5D (2 m to 67 cm) than the trifocal group; the MDs were −0.03, −0.06, and −0.04 (95% CI: −0.04, −0.01; −0.10, −0.01; −0.08, −0.00) for −0.5D, −1D, and −1.5D, respectively. For RCTs, the EDOF group also performed better at these defocus levels than the trifocal group, even without statistical differences. However, for near visual acuity, the trifocal group performed better than the EDOF group from −2.5D to −4D (40 cm to 25 cm).

3.4. Secondary Outcomes

3.4.1. Monocular and Binocular Corrected Visual Acuity. Monocular corrected visual acuity was reported in four studies (Figure 7). Three studies provided details on binocular CDVA, whereas two studies provided data on binocular DCIVA and DCNVA (Figure 8). There was no significant difference in monocular and binocular CDVA and DCIVA between groups. The EDOF group showed worse monocular (MD: 0.14, 95% CI: 0.06 to 0.22, \( P = 0.0004 \), logMAR) and binocular (MD: 0.12, 95% CI: 0.03 to 0.20, \( P = 0.01 \), logMAR) DCNVA than the trifocal group.

3.4.2. Refraction. Spherical equivalent, residual sphere, and residual astigmatism were reported in nine, four, and five studies, respectively (Figure 9). There was no significant difference in spherical equivalent and residual sphere between groups in studies that targeted emmetropic eyes. There was also no significant difference in residual astigmatism between groups. For RCTs, the EDOF group showed worse monocular (MD: 0.14, 95% CI: 0.06 to 0.22, \( P = 0.0004 \), logMAR) and binocular (MD: 0.12, 95% CI: 0.03 to 0.20, \( P = 0.01 \), logMAR) DCNVA than the trifocal group.

3.4.3. Contrast Sensitivity. The Functional Acuity Contrast Test was used to test CS in three studies [18, 35, 36], the Optec 6500 was used in one study [34], and the CSV-1000 system was used in one study [32]. There was no statistical difference in mean CS under photopic (SMD: 0.09, 95% CI: −0.19 to 0.37, \( P = 0.52 \)) and mesopic conditions (SMD: 0.04, 95% CI: −0.24 to 0.32, \( P = 0.79 \)) between the EDOF and trifocal groups (Figure 10); no heterogeneity was noted either. Overall, there was no statistical difference in CS from...
1.5 cycles per degree (cpd) to 18 cpd between the two IOL groups, whether under photopic or mesopic conditions (Table S3). A subgroup analysis based on the testing methods for CS was conducted. The modulation transfer function (MTF) was used to reflect CS in three studies [30, 31, 38]. The MTF for EDOF IOLs and TIOLs was also reported to be comparable at different cpd and with 3 mm and 5 mm pupil diameters (PD).

3.4.4. Aberrations. Aberrations were reported in five studies (Table 3). Quantitative analysis was not appropriate since different pupil sizes and different aberration types were measured in each study. Therefore, the results were summarized (Table 3). No significant difference was found in most studies, except in Monaco’s study, in which patients in the EDOF group with a 5.0 mm PD had significantly higher values of intraocular aberrations and total aberrations than the patients in the trifocal group.

3.4.5. Spectacle Independence. Total spectacle independence was reported in five studies. Spectacle independence for distance and intermediate vision was reported in four studies, whereas spectacle independence for near vision was reported in five studies (Figure 11). The EDOF group had a significantly lower total spectacle independence (RR: 0.74, 95% CI: 0.63 to 0.87, \( P = 0.0004 \)) and a lower spectacle independence for near vision (RR: 0.82, 95% CI: 0.68 to 0.99, \( P = 0.04 \)) than the trifocal group. There was no significant difference in spectacle independence for distance and intermediate vision between the groups. The \( I^2 \) was 0, indicating that there was no significant heterogeneity in different studies.

3.4.6. Quality of Vision and Patient Satisfaction. Quality of vision and patient satisfaction were assessed in 11 studies through questionnaires. Patient satisfaction after implantation of both EDOF IOLs and TIOLs was high; 80–100% of patients were satisfied with TIOLs, whereas 90%–100% of patients were satisfied with EDOF IOLs [18, 34]. More than 75% of patients responded that they would choose the same lens again [18, 34, 39], whereas 92% with AT LISA tri 839MP IOL implants and 93% of patients with Symfony IOL implants would recommend the implanted IOL to family or friends [32].

Halos were reported as the most frequent, severe, and bothersome visual symptom in both groups [31]. However, visual disturbance did not have a significant influence on patients [30, 34]. A well-validated questionnaire, the Quality of Vision (QoV) questionnaire [42], was
| Study                        | Selection | Comparability | Outcome assessment |
|------------------------------|-----------|---------------|--------------------|
|                              | Representativeness of the treatment arm | Selection of the comparative treatment arm(s) | Ascertainment of treatment regimen | Outcome was not present at the start of the study | Comparability between patients in different treatment arms: age, preoperative conditions | Assessment of outcome with independency or with records | Adequacy of follow-up duration (more than three months) | Lost to follow-up (acceptable - less than 10%) | Total quality score |
| Ruiz-Mesa et al. 2017 [18]  | ☆         | ☆             | ☆                  | ☆                              | ☆|☆|☆|☆|8 |
| Mencucci et al. 2018 [34]   | ☆         | ☆             | ☆                  | ☆                              | ☆|☆|☆|☆|9 |
| Ruiz-Mesa et al. 2018 [35]   | ☆         | ☆             | ☆                  | ☆                              | ☆|☆|☆|☆|8 |
| Escandon-Garcia et al. 2018 [36] | ☆     | ☆             | ☆                  | ☆                              | ☆|☆|☆|☆|8 |
| de Medeiros et al. 2019 [37] | ☆         | ☆             | ☆                  | ☆                              | ☆|☆|☆|☆|9 |
| Singh et al. 2019 [38]       | ☆         | ☆             | ☆                  | ☆                              | ☆|☆|☆|☆|9 |
| Rodov et al. 2019 [39]       | ☆         | ☆             | ☆                  | ☆                              | ☆|☆|☆|☆|5 |
| Lin et al. 2019 [41]         | ☆         | ☆             | ☆                  | ☆                              | ☆|☆|☆|☆|8 |

Each item can get at most one star (☆) in "selection" and "outcome assessment," and two stars (☆☆) at most in "comparability." The total number of stars ranges from 0 to 9; studies that score 0 to 3, 4 to 6, and 7 to 9 are considered have a low, moderate, and high quality, respectively.
### Study or Subgroup

| Study or Subgroup | EDOF Mean | EDOF SD | EDOF Total | trifocal Mean | trifocal SD | trifocal Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference trifocal |
|-------------------|-----------|---------|------------|--------------|------------|----------------|------------|------------------------------------|------------------------|
| Bohm 2019         | 0.04      | 0.09    | 52         | 0.07         | 0.12       | 54             | 25.1       | −0.03 [−0.07, 0.01]                |                        |
| Lin 2019          | 0.13      | 0.11    | 26         | 0.04         | 0.09       | 24             | 22.9       | 0.09 [0.03, 0.15]                  |                        |
| Mencucci 2018     | 0.12      | 0.08    | 40         | 0.18         | 0.09       | 80             | 26.1       | −0.06 [−0.09, −0.03]               |                        |
| Monaco 2017       | 0.27      | 0.08    | 40         | 0.23         | 0.07       | 40             | 26.0       | 0.04 [0.01, 0.07]                  |                        |
| Total (95% CI)    | 158       | 198     | 100.0      |              |             |                | 100.0      | 0.01 [−0.05, 0.07]                 |                        |

Heterogeneity: $\tau^2 = 0.00; \chi^2 = 31.46, df = 3 (P < 0.0001); I^2 = 90%$
Test for overall effect: $Z = 2.53 (P = 0.01)$

### Study or Subgroup

| Study or Subgroup | EDOF Mean | EDOF SD | EDOF Total | trifocal Mean | trifocal SD | trifocal Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference trifocal |
|-------------------|-----------|---------|------------|--------------|------------|----------------|------------|------------------------------------|------------------------|
| Bohm 2019         | 0.3       | 0.15    | 52         | 0.09         | 0.12       | 54             | 25.0       | 0.21 [0.16, 0.26]                  |                        |
| Lin 2019          | 0.15      | 0.1     | 26         | 0.05         | 0.17       | 24             | 22.4       | 0.10 [0.02, 0.18]                  |                        |
| Mencucci 2018     | 0.38      | 0.11    | 40         | 0.19         | 0.05       | 80             | 26.2       | 0.19 [0.15, 0.23]                  |                        |
| Monaco 2017       | 0.07      | 0.08    | 40         | 0.02         | 0.06       | 40             | 26.5       | 0.05 [0.02, 0.08]                  |                        |
| Total (95% CI)    | 158       | 198     | 100.0      |              |             |                | 100.0      | 0.14 [0.05, 0.22]                  |                        |

Heterogeneity: $\tau^2 = 0.01; \chi^2 = 45.88, df = 3 (P < 0.0001); I^2 = 93%$
Test for overall effect: $Z = 3.12 (P = 0.002)$

### Study or Subgroup

| Study or Subgroup | EDOF Mean | EDOF SD | EDOF Total | trifocal Mean | trifocal SD | trifocal Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference trifocal |
|-------------------|-----------|---------|------------|--------------|------------|----------------|------------|------------------------------------|------------------------|
| de Medeiros 2019  | 0.00      | 0.05    | 14         | 0.09         | 0.1        | 13             | 13.7       | −0.09 [−0.15, −0.03]               |                        |
| Escandon–Garcia 2018 | 0.08  | 0.1     | 15         | 0.08         | 0.09       | 30             | 13.8       | 0.00 [−0.06, 0.06]                 |                        |
| Mencucci 2018     | −0.04     | 0.05    | 20         | −0.01        | 0.06       | 40             | 22.6       | −0.03 [−0.06, −0.00]               |                        |
| Ruiz–Mesa 2017    | 0.01      | 0.02    | 20         | 0.01         | 0.03       | 20             | 26.0       | 0.00 [−0.02, 0.02]                 |                        |
| Ruiz–Mesa 2018    | 0.05      | 0.12    | 14         | 0.03         | 0.03       | 20             | 12.8       | 0.05 [−0.01, 0.11]                 |                        |
| Webers 2020       | 0.01      | 0.12    | 14         | −0.05        | 0.07       | 13             | 11.0       | 0.06 [−0.01, 0.13]                 |                        |
| Total (95% CI)    | 97        | 136     | 100.0      |              |             |                | 100.0      | −0.01 [−0.04, 0.03]                |                        |

Heterogeneity: $\tau^2 = 0.00; \chi^2 = 16.74, df = 5 (P = 0.005); I^2 = 70%$
Test for overall effect: $Z = 3.38 (P = 0.001)$

---

**Figure 4:** Forest plot of monocular uncorrected visual acuity. (a) Uncorrected distance visual acuity; (b) uncorrected intermediate visual acuity; and (c) uncorrected near visual acuity. EDOF, extended depth-of-focus; SD, standard deviation; CI, confidence interval; IV, inverse variance.

**Figure 5:** Continued.
### Study or Subgroup

|                  | EDOF Mean | SD | Total | trifocal Mean | SD | Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|------------------|-----------|----|-------|---------------|----|-------|------------|-------------------------------------|-------------------------------------|
| de Medeiros 2019 | 0.2       | 0.04| 14     | 0.39          | 0.09| 13    | 23.4       | −0.19 [−0.24, −0.14]                |                                    |
| Mencucci 2018    | 0.07      | 0.07| 20     | 0.14          | 0.07| 40    | 25.6       | −0.07 [−0.11, −0.03]                |                                    |
| Ruiz–Mesa 2017   | 0.09      | 0.08| 20     | 0.11          | 0.08| 20    | 23.9       | −0.02 [−0.07, 0.03]                 |                                    |
| Webers 2020      | −0.02     | 0.03| 14     | 0.01          | 0.03| 13    | 27.1       | −0.03 [−0.05, −0.01]                |                                    |
| **Total (95% CI)** | 68       | 86 | 100.0 | −0.08         | 0.14| 100.0 | 23.4       | −0.19 [−0.24, −0.14]                |                                    |

Heterogeneity: Tau² = 0.00; Chi² = 31.90, df = 3 (P = 0.00001); I² = 91%
Test for overall effect: Z = 2.36 (P = 0.02)

### (b) 1.6.1 emmetropia

|                  | EDOF Mean | SD | Total | trifocal Mean | SD | Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|------------------|-----------|----|-------|---------------|----|-------|------------|-------------------------------------|-------------------------------------|
| Mencucci 2018    | 0.25      | 0.08| 20     | 0.17          | 0.05| 40    | 27.9       | 0.08 [0.04, 0.12]                  |                                    |
| Ruiz–Mesa 2017   | 0.17      | 0.06| 20     | 0.06          | 0.07| 20    | 27.2       | 0.11 [0.07, 0.15]                  |                                    |
| **Subtotal (95% CI)** | 40       | 60 | 55.2  | 0.09 [0.06, 0.12]                   |                                    |

Heterogeneity: Tau² = 0.00; Chi² = 1.11, df = 1 (P = 0.29); I² = 10%
Test for overall effect: Z = 6.29 (P < 0.00001)

### (c) 1.6.2 micro–monovision

|                  | EDOF Mean | SD | Total | trifocal Mean | SD | Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|------------------|-----------|----|-------|---------------|----|-------|------------|-------------------------------------|-------------------------------------|
| Webers 2020      | 0.09      | 0.05| 14     | 0.04          | 0.07| 13    | 25.3       | 0.05 [0.00, 0.10]                  |                                    |
| **Subtotal (95% CI)** | 14       | 13 | 13.4  | 0.05 [0.00, 0.10]                   |                                    |

Heterogeneity: Not applicable
Test for overall effect: Z = 2.12 (P = 0.03)

### (b) 1.6.3 micro–monovision or emmetropia

|                  | EDOF Mean | SD | Total | trifocal Mean | SD | Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|------------------|-----------|----|-------|---------------|----|-------|------------|-------------------------------------|-------------------------------------|
| de Medeiros 2019 | 0.16      | 0.08| 14     | −0.01         | 0.09| 13    | 19.6       | 0.17 [0.11, 0.23]                  |                                    |
| **Subtotal (95% CI)** | 14       | 13 | 13.4  | 0.17 [0.11, 0.23]                   |                                    |

Heterogeneity: Not applicable
Test for overall effect: Z = 5.17 (P < 0.00001)

|                  | EDOF Mean | SD | Total | trifocal Mean | SD | Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|------------------|-----------|----|-------|---------------|----|-------|------------|-------------------------------------|-------------------------------------|
| **Total (95% CI)** | 68       | 86 | 100.0 | 0.10 [0.06, 0.14]                   |                                    |

Heterogeneity: Tau² = 0.00; Chi² = 9.94, df = 3 (P = 0.02); I² = 70%
Test for overall effect: Z = 4.60 (P < 0.00001)
Test for subgroup differences: Chi² = 8.82, df = 3 (P = 0.01); I² = 77.3%

**Figure 5:** Forest plot of binocular uncorrected visual acuity. (a) Uncorrected distance visual acuity; (b) uncorrected intermediate visual acuity; and (c) uncorrected near visual acuity. EDOF, extended depth-of-focus; SD, standard deviation; CI, confidence interval; IV, inverse variance.
Figure 6: (a) The overall defocus curve; (b) the defocus curve synthesized from randomized controlled trials (RCTs); and (c) the defocus curve synthesized from prospective comparative studies. The bar represents the standard deviation. * $P < 0.05$, ** $P < 0.01$. EDOF, extended depth-of-focus.

Figure 7: Forest plot of monocular corrected visual acuity. (a) Corrected distance visual acuity; (b) distance corrected intermediate visual acuity; and (c) distance corrected near visual acuity. EDOF, extended depth-of-focus; SD, standard deviation; CI, confidence interval; IV, inverse variance.
Heterogeneity: Tau² = 0.00; Chi² = 103.94, d = 0.28)

Ruiz–Mesa 2018

Total (95% CI)

Heterogeneity: Tau² = 0.00; Chi² = 173.65, d = 1.09 (P = 0.28)

Test for overall effect: Z = 0.01)

Ruiz-Mesa 2017

(continued)

Study or Subgroup

Heterogeneity: Tau² = 0.00; Chi² = 2.09, d = 1 (P = 0.15); I² = 52%

Test for overall effect: Z = 0.55 (P < 0.0001)

Heterogeneity: Not applicable

Test for overall effect: Z = 4.35 (P < 0.0001)

6.1.3 emmetropic or micro–monovision

de Medeiros 2019

Ruiz-Mesa 2018

Subtotal (95% CI)

Heterogeneity: Tau² = 0.00; Chi² = 2.09, d = 1 (P = 0.15); I² = 52%

Test for overall effect: Z = 4.05 (P < 0.0001)

Total (95% CI)

Heterogeneity: Tau² = 0.01; Chi² = 173.65, d = 8 (P < 0.00001); I² = 95%

Test for overall effect: Z = 2.95 (P = 0.003)

Test for subgroup differences: Chi² = 23.26, d = 2 (P < 0.00001); I² = 91.4%

(a)

Heterogeneity: Tau² = 0.00; Chi² = 8.29, d = 1 (P = 0.004); I² = 88%

Test for overall effect: Z = 2.57 (P = 0.01)

Total (95% CI)

Heterogeneity: Tau² = 0.00; Chi² = 5.44, d = 2 (P = 0.010); I² = 78%

Test for overall effect: Z = 4.35 (< 0.0001)

(a)

6.1.2 micro–monovision

Webers 2020

Subtotal (95% CI)

Heterogeneity: Not applicable

Test for overall effect: Z = 4.35 (P < 0.0001)

6.1.1 emmetropic

Bohm 2019

Escandon–Garcia 2018

Mencucci 2018

Mencucci 2018

Monaco 2017

Singh 2019

Subtotal (95% CI)

Heterogeneity: Tau² = 0.00; Chi² = 103.94, d = 5 (P < 0.0001); I² = 95%

Test for overall effect: Z = 0.60 (P = 0.55)

Study or Subgroup

EDOF trifocal Mean Difference

IV, Random, 95% CI

Mean Difference

Mean Difference

EDOF trifocal Mean Difference

IV, Random, 95% CI

Mean Difference

Mean Difference

Subtotal (95% CI)

Heterogeneity: Tau² = 0.00; Chi² = 8.29, d = 1 (P = 0.004); I² = 88%

Test for overall effect: Z = 2.57 (P = 0.01)

(a)

Study or Subgroup

EDOF trifocal Mean Difference

IV, Random, 95% CI

Mean Difference

Mean Difference

Subtotal (95% CI)

Heterogeneity: Tau² = 0.00; Chi² = 5.44, d = 2 (P = 0.010); I² = 78%

Test for overall effect: Z = 4.35 (< 0.0001)

(b)

Study or Subgroup

EDOF trifocal Mean Difference

IV, Random, 95% CI

Mean Difference

Mean Difference

Subtotal (95% CI)

Heterogeneity: Tau² = 0.00; Chi² = 9.24, d = 1 (P = 0.004); I² = 82%

Test for overall effect: Z = 4.05 (< 0.0001)

(c)

Figure 8: Forest plot of binocular corrected visual acuity. (a) Corrected distance visual acuity; (b) distance corrected intermediate visual acuity; and (c) distance corrected near visual acuity. EDOF, extended depth-of-focus; SD, standard deviation; CI, confidence interval; IV, inverse variance.

Figure 9: Continued.
Heterogeneity: $\tau^2 = 0.00; \chi^2 = 1.25, d_f = 1 (P = 0.21); I^2 = 36\%$
Test for overall effect: $Z = 1.63 (P = 0.10)$

6.2.1 emmetropic

| Study or Subgroup | EDOF Mean | SD | Total | trifocal Mean | SD | Total | Weight | Mean difference IV, random, 95% CI |
|------------------|-----------|----|-------|--------------|----|-------|--------|----------------------------------|
| Bohm 2019        | 0.09      | 0.27 | 52    | 0.21         | 0.27 | 54    | 29.0   | $-0.12 [-0.22, -0.02]$           |
| Ruiz-Mesa 2017   | $-0.11$   | 0.19 | 40    | $-0.08$      | 0.25 | 40    | 29.3   | $-0.03 [-0.13, 0.07]$            |
| Subtotal (95% CI)| 92        |     | 94    | 58.4        | 8.07 |       | $-0.16, 0.01$                     |

Heterogeneity: $\tau^2 = 0.00; \chi^2 = 1.55, d_f = 1 (P = 0.21); I^2 = 36\%$
Test for overall effect: $Z = 1.63 (P = 0.10)$

6.2.2 micro-metamoropia

| Study or Subgroup | EDOF Mean | SD | Total | trifocal Mean | SD | Total | Weight | Mean difference IV, random, 95% CI |
|------------------|-----------|----|-------|--------------|----|-------|--------|----------------------------------|
| Webers 2020      | $-0.09$   | 0.55 | 28    | 0.4          | 0.23 | 26    | 20.9   | $-0.49 [-0.71, -0.27]$           |
| Subtotal (95% CI)| 68        |     | 106   | 41.6        |     |       | $-0.58, -0.22$                    |

Heterogeneity: $\tau^2 = 0.00; \chi^2 = 1.25, d_f = 1 (P = 0.26); I^2 = 20\%$
Test for overall effect: $Z = 4.45 (P < 0.00001)$

Total (95% CI)

| Weight | Mean difference IV, random, 95% CI |
|--------|----------------------------------|
| 160    | $-0.21 [-0.38, -0.04]$           |

Test for subgroup differences: $\chi^2 = 10.58, d_f = 3 (P = 0.002)$

Test for overall effect: $Z = 2.42 (P = 0.01)$

(continued)

Figure 9: Forest plot of postoperative refraction. (a) Spherical equivalent; (b) residual sphere; and (c) residual astigmatism. EDOF, extended depth-of-focus; SD, standard deviation; CI, confidence interval; IV, inverse variance.

Figure 10: Forest plots of mean contrast sensitivity (CS). (a) The forest plot of CS under photopic conditions and (b) the forest plot of CS under mesopic conditions. EDOF, extended depth-of-focus; SD, standard deviation; CI, confidence interval; IV, inverse variance.
used to assess visual disturbance in three studies [31, 36, 38]; a higher score in the QoV questionnaire means a worse quality of vision. In all studies, the mean QoV score was not statistically significant between groups [31, 38], except in the study by Escandón-García et al., in which patients implanted with Symfony IOLs showed higher values in all categories (frequency, severity, and bothersome) than patients implanted with TIOLs; the difference was statistically significant for the “bothersome” subscale. However, in the study by Gil et al., in which the Visual Function Index-14 questionnaire was used, the median score for life quality was significantly higher in the EDOF group than in the trifocal group. There were no statistically significant differences in Strehl ratios between groups.

3.4.7. Complications and Adverse Events. Three studies reported postoperative complications and adverse events. In the study by Webers et al., one patient in both groups underwent neodymium:YAG laser capsulotomy treatment for PCO 3 months postoperatively [18]. In the study by Ruiz-Mesa et al. 5% of patients developed PCO in the Finevision group, while no patients had PCO in the EDOF group 12 months postoperatively [31]. Monaco et al. reported that there were no complications or adverse events in both groups of patients 4 months postoperatively [32].

3.5. Publication Bias. All indicators were tested by using Egger’s test to assess publication bias (Table S4). Publication bias was found in spectacle independence for distance vision, visual acuity at a defocus level of +1D, and CS (1.5cpd, mesopic). We used the trim-and-fill method to adjust these indicators, after which the results remained unchanged (Table S5).

4. Discussion

In this study, we compared the outcomes of the implantation of TIOLs and TECNIS Symfony IOLs. The results indicated that the TECNIS Symfony IOLs provide significantly better intermediate vision, but worse near vision than TIOLs. Spectacle independence was found to be lower for near vision and for any purpose in the EDOF group than in the trifocal group. Distance visual acuity, CS, and aberrations were comparable between the two groups. Patient satisfaction did not differ between the two groups; most of the patients were satisfied with both IOLs.

A previous meta-analysis showed that there is no statistically significant difference between EDOF IOLs and TIOLs in terms of binocular UDVA [11], a finding which is consistent with our results. Furthermore, we found that distance visual acuity with the two types of IOL is comparable, whether monocular, binocular, uncorrected, or corrected. This result means that patients implanted with EDOF IOLs could have great distance visual acuity, even comparable with that of monofocal IOLs in previous studies [6, 7].

In *in vitro* experiments, EDOF technology provides clear and focused vision across near, intermediate, and distance ranges [43]. In population-based research, EDOF has been proven to perform better than monofocal IOLs at intermediate and near distances [6, 7]. Gatinel et al. measured
### Forest Plot

**Figure 11:** Forest plot of postoperative spectacle independence. (a) Total spectacle independence; (b) for distance vision; (c) for intermediate vision; and (d) for near vision. EDOF, extended depth-of-focus; CI, confidence interval.

| Study or Subgroup | EDOF Events | EDOF Total | trifocal Events | trifocal Total | Weight (%) | Risk Ratio M−H, Fixed, 95% CI | Risk Ratio M−H, Fixed, 95% CI | Heterogeneity: Chi² = 5.05, df = 4 (P = 0.28); I² = 21% Test for overall effect: Z = 3.56 (P = 0.0004) |
|-------------------|-------------|------------|----------------|---------------|------------|-------------------------------|-------------------------------|----------------------------------------------------------------------------------|
| Bohm 2019         | 17          | 24         | 25             | 26            | 23.2       | 0.74 [0.56, 0.96]             |                               |                                                                                  |
| Mencucci 2018     | 12          | 20         | 14             | 20            | 13.6       | 0.86 [0.54, 1.36]             |                               |                                                                                  |
| Monaco 2017       | 14          | 20         | 17             | 20            | 16.5       | 0.82 [0.59, 1.16]             |                               |                                                                                  |
| Rodov 2019        | 24          | 50         | 41             | 50            | 39.7       | 0.59 [0.43, 0.80]             |                               |                                                                                  |
| Webers 2020       | 9           | 14         | 7              | 13            | 7.0        | 1.19 [0.63, 2.26]             |                               |                                                                                  |
| **Total (95% CI)**| **128**     | **129**    | **100.0**      |               | **0.74 [0.63, 0.87]**         |                               |                                                                                  |

| Study or Subgroup | EDOF Events | EDOF Total | trifocal Events | trifocal Total | Weight (%) | Risk Difference M−H, Fixed, 95% CI | Risk Difference M−H, Fixed, 95% CI | Heterogeneity: Chi² = 0.24, df = 3 (P = 0.97); I² = 0% Test for overall effect: Z = 0.26 (P = 0.79) |
|-------------------|-------------|------------|----------------|---------------|------------|------------------------------------|------------------------------------|----------------------------------------------------------------------------------|
| Mencucci 2018     | 20          | 20         | 20             | 20            | 15.4       | 0.00 [−0.09, 0.09]                 |                                   |                                                                                  |
| Monaco 2017       | 17          | 20         | 18             | 20            | 15.4       | −0.05 [−0.25, 0.15]               |                                   |                                                                                  |
| Rodov 2019        | 47          | 50         | 47             | 50            | 38.5       | 0.00 [−0.09, 0.09]                 |                                   |                                                                                  |
| Singh 2019        | 38          | 40         | 38             | 40            | 30.8       | 0.00 [−0.10, 0.10]                 |                                   |                                                                                  |
| **Total (95% CI)**| **130**     | **130**    | **100.0**      |               | **0.00 [−0.07, 0.05]**            |                                   |                                                                                  |

| Study or Subgroup | EDOF Events | EDOF Total | trifocal Events | trifocal Total | Weight (%) | Risk Ratio M−H, Random, 95% CI | Risk Ratio M−H, Random, 95% CI | Heterogeneity: Tau² = 0.02; Chi² = 9.37, df = 4 (P = 0.05); I² = 57% Test for overall effect: Z = 2.10 (P = 0.04) |
|-------------------|-------------|------------|----------------|---------------|------------|-------------------------------|-------------------------------|----------------------------------------------------------------------------------|
| Mencucci 2018     | 12          | 20         | 14             | 20            | 11.5       | 0.86 [0.54, 1.36]             |                               |                                                                                  |
| Monaco 2017       | 15          | 20         | 18             | 20            | 19.5       | 0.83 [0.62, 1.12]             |                               |                                                                                  |
| Rodov 2019        | 22          | 50         | 39             | 50            | 16.4       | 0.56 [0.40, 0.80]             |                               |                                                                                  |
| Ruiz-Mesa 2017    | 18          | 20         | 19             | 20            | 27.8       | 0.95 [0.79, 1.13]             |                               |                                                                                  |
| Singh 2019        | 30          | 40         | 35             | 40            | 24.9       | 0.86 [0.69, 1.06]             |                               |                                                                                  |
| **Total (95% CI)**| **150**     | **150**    | **100.0**      |               | **0.82 [0.68, 0.99]**           |                               |                                                                                  |

| Study or Subgroup | EDOF Events | EDOF Total | trifocal Events | trifocal Total | Weight (%) | Risk Ratio M−H, Random, 95% CI | Risk Ratio M−H, Random, 95% CI | Heterogeneity: Tau² = 0.02; Chi² = 9.37, df = 4 (P = 0.05); I² = 57% Test for overall effect: Z = 2.10 (P = 0.04) |
|-------------------|-------------|------------|----------------|---------------|------------|-------------------------------|-------------------------------|----------------------------------------------------------------------------------|
| Mencucci 2018     | 12          | 20         | 14             | 20            | 11.5       | 0.86 [0.54, 1.36]             |                               |                                                                                  |
| Monaco 2017       | 15          | 20         | 18             | 20            | 19.5       | 0.83 [0.62, 1.12]             |                               |                                                                                  |
| Rodov 2019        | 22          | 50         | 39             | 50            | 16.4       | 0.56 [0.40, 0.80]             |                               |                                                                                  |
| Ruiz-Mesa 2017    | 18          | 20         | 19             | 20            | 27.8       | 0.95 [0.79, 1.13]             |                               |                                                                                  |
| Singh 2019        | 30          | 40         | 35             | 40            | 24.9       | 0.86 [0.69, 1.06]             |                               |                                                                                  |
| **Total (95% CI)**| **150**     | **150**    | **100.0**      |               | **0.82 [0.68, 0.99]**           |                               |                                                                                  |

---

Journal of Ophthalmology
and plotted through-focus MTF curves for 2, 3, and 3.75 mm pupil apertures; they discovered two MTF peaks for distance and intermediate vision with EDOF IOLs [44]. Correspondingly, the EDOF IOLs displayed a range of vision with sufficient resolution from 0 to +2D (from distance to 50 cm) and a sharp drop of contrast resolution at near distances [44]. The TIOLs displayed three MTF peaks for distance, intermediate, and near vision; however, the intermediate peak was relatively flat [44]. In the present study, patients implanted with EDOF IOLs had a significantly better binocular UNVA than those with TIOL implants; this is in contrast to the result of the previous meta-analysis, in which there was no difference in binocular UNVA between the two groups [11]. This difference may be due to the difference in the number of studies included in the meta-analyses.

EDOF IOLs provide patients with a better postoperative near visual acuity than multifocal IOLs [11]. However, the results of the present study indicate that they are still inferior to TIOLs. Spectacle independence for near vision was also significantly lower in the EDOF group than in the trifocal group in the present study. Recently, a new strategy called micro-monovision was proposed; it is reported to provide significantly better intermediate and near visual acuity than monofocal IOLs [11]. However, the advantages of Symfony IOLs over TIOLs in terms of CS, aberrations, and visual disturbance are not apparent. However, more studies are needed in the future to verify this conclusion.

In conclusion, Symfony IOLs and TIOLs provide comparable distance vision. However, Symfony IOLs provide better intermediate vision and worse near vision than TIOLs. The advantages of Symfony IOLs over TIOLs in terms of CS, aberrations, and visual disturbance are not significant. Patients are satisfied with both types of IOLs. Our study provides more evidence for surgeons to select more suitable IOLs for cataract patients. In the future, designers can focus on the defects of these two types of IOLs more specifically to improve the design principles so that patients can obtain a higher visual quality.

**Data Availability**

The datasets supporting the conclusions of this article are all included within the article and its additional file.


**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Yining Guo, Yinhao Wang, Ran Hao contributed equally to this study as co-first authors. Y. G. and Y. W. independently extracted data from the included studies. Discrepancies between the decisions of the two reviewers were resolved by consensus; X. J. was consulted when necessary. R. H., X. J., and Z. L. participated in the data analysis. Y. G. and Y. W. were major contributors in writing the manuscript. X. L. revised the manuscript. All authors read, commented, and approved the final manuscript.

**Acknowledgments**

This work was supported by Natural Science Foundation of Beijing Municipality (7202229).

**Supplementary Materials**

Table 1S: parameters of the included intraocular lenses. Table 2Sa: overall mean values and 95% CI of visual acuity (logMAR) at different defocus. Table 2Sb: mean values and 95% CI of visual acuity (logMAR) at different defocus from non-RCTs. Table 2Sc: mean values and 95% CI of visual acuity (logMAR) at different defocus from RCTs. Table 2Sd: MD and 95% CI of visual acuity (logMAR) at different defocus across EDOF IOLs and TIOLs. Table 3S: contrast sensitivity difference between EDOF IOLs and TIOLs. Table 4S: Egger’s test for each outcome. Table 5S: trim-and-fill method for the adjustment of publication bias. (Supplementary Materials)

**References**

[1] K. Negishi, K. Hayashi, K. Kamiya et al., “Nationwide prospective cohort study on cataract surgery with multifocal intraocular lens implantation in Japan,” *American Journal of Ophthalmology*, vol. 208, pp. 133–144, 2019.

[2] K. Cao, D. S. Friedman, S. Jin et al., “Multifocal versus monofocal intraocular lenses for age-related cataract patients: a system review and meta-analysis based on randomized controlled trials,” *Survey of Ophthalmology*, vol. 64, no. 5, pp. 647–658, 2019.

[3] S. C. Schallhorn, D. Teenan, J. A. Venter, S. J. Hannan, and J. M. Schallhorn, “Initial clinical outcomes of a new extended depth of focus intraocular lens,” *Journal of Refractive Surgery*, vol. 35, pp. 426–433, 2019.

[4] T. B. Ferreira, J. Pinheiro, L. Zabala, and F. J. Ribeiro, “Comparative analysis of clinical outcomes of a monofocal and an extended-range-of-vision intraocular lens in eyes with previous myopic laser in situ keratomileusis,” *Journal of Cataract and Refractive Surgery*, vol. 44, no. 2, pp. 149–155, 2018.

[5] L. Kelava, H. Baric, M. Bucić, I. Čima, and V. Trkulja, “Monovision versus multifocality for presbyopia: systematic review and meta-analysis of randomized controlled trials,” *Advances in Therapy*, vol. 34, no. 8, pp. 1815–1839, 2017.

[6] E. Pedrotti, E. Bruni, E. Bonacci, R. Badalamenti, R. Mastropasqua, and G. Marchini, “Comparative analysis of the clinical outcomes with a monofocal and an extended range of vision intraocular lens,” *Journal of Refractive Surgery*, vol. 32, pp. 436–442, 2016.

[7] E. Pedrotti, C. Chiareggio, P. M. Talli et al., “Extended depth of focus versus monofocal IOLs: objective and subjective visual outcomes,” *Journal of Refractive Surgery*, vol. 36, pp. 214–222, 2020.

[8] D. R. H. Breyer, H. Kaymak, T. Ax, F. T. A. Kretz, G. U. Auffarth, and P. R. Hagen, “Multifocal intraocular lenses and extended depth of focus intraocular lenses,” *Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)*, vol. 6, pp. 339–349, 2017.

[9] J. F. Alfonso, L. Fernández-Vega, C. Puchades, and R. Montés-Micó, “Intermediate visual function with different multifocal intraocular lens models,” *Journal of Cataract and Refractive Surgery*, vol. 36, no. 5, pp. 733–739, 2010.

[10] S. R. de Silva, J. R. Evans, V. Kirthi, M. Ziaei, and M. Leyland, “Multifocal versus monofocal intraocular lenses after cataract extraction,” *Cochrane Database of Systematic Reviews*, vol. 12, no. 12, 2016.

[11] J. Liu, Y. Dong, and Y. Wang, “Efficacy and safety of extended depth of focus intraocular lenses in cataract surgery: a systematic review and meta-analysis,” *BMC Ophthalmology*, vol. 19, no. 1, p. 198, 2019.

[12] Y. Lee, G. Labuz, H.-S. Son, T. M. Yildirim, R. Khoramnia, and G. U. Auffarth, “Assessment of the image quality of extended depth-of-focus intraocular lens models in polychromatic light,” *Journal of Cataract and Refractive Surgery*, vol. 46, no. 1, pp. 108–115, 2020.

[13] G. Savini, D. Schiano-Lomoriello, N. Balducci, and P. Barboni, “Visual performance of a new extended depth-of-focus intraocular lens compared to a distance-dominant diffractive multifocal intraocular lens,” *Journal of Refractive Surgery*, vol. 34, pp. 228–235, 2018.

[14] B. Cochener, “Clinical outcomes of a new extended range of vision intraocular lens: international Multicenter Concerto Study,” *Journal of Cataract and Refractive Surgery*, vol. 42, no. 9, pp. 1268–1275, 2016.

[15] A. Domínguez-Vicent, J. J. Esteve-Taboada, A. J. Del Aguila-Carrasco, T. Ferrer-Blasco, and R. Montés-Micó, “In vitro optical quality comparison between the mimy well ready progressive multifocal and the TECNIS Symfony,” *Graefe’s Archive for Clinical and Experimental Ophthalmology*, vol. 254, no. 7, pp. 1387–1397, 2016.

[16] T. Kohnen and R. Suryakumar, “Extended depth-of-focus technology in intraocular lenses,” *Journal of Cataract and Refractive Surgery*, vol. 46, no. 2, pp. 298–304, 2020.

[17] D. H. Chang, D. P. Janakiraman, P. J. Smith et al., “Visual outcomes and safety of the TECNIS Symfony intraocular lens: results of a pivotal clinical trial,” *Journal of Cataract and Refractive Surgery*, 2021.

[18] R. Ruiz-Mesa, A. Abengózar-Vela, A. Aramburu, and M. Ruiz-Santos, “Comparison of visual outcomes after bilateral implantation of extended range of vision and trifocal intraocular lenses,” *European Journal of Ophthalmology*, vol. 27, no. 4, pp. 460–465, 2017.

[19] A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” *Journal of Clinical Epidemiology*, vol. 62, no. 10, pp. e1–e34, 2009.
[20] J. P. T. Higgins, D. G. Altman, P. C. Gotzsche et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” BMJ, vol. 343, p. d5928, 2011.

[21] G. Wells, “The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses,” 2000.

[22] I. Tarib, I. Kaisier, and C. Herbers, “Comparison of visual outcomes and patient satisfaction after bilateral implantation of an EDOF IOL and a mix-and-match approach,” Journal of Refractive Surgery, vol. 35, pp. 408–416, 2019.

[23] A. L. de Medeiros, A. G. de Araujo Rolim, A. F. P. Motta et al., “Comparison of visual outcomes after bilateral implantation of a diffractive trifocal intraocular lens and blended implantation of an extended depth of focus intraocular lens with a diffractive bifocal intraocular lens,” Clinical Ophthalmology, vol. 11, pp. 1911–1916, 2017.

[24] X. Liang, “Withdrawn-visual quality analysis of three kinds of intraocular lens for cataracts with highly myopic patients,” Investigative Ophthalmology & Visual Science, vol. 60, 2019.

[25] M. Attia, R. Khoramnia, T. Rabsilber, M. P. Holzer, and G. U. Auffarth, “Comparison of the functional results of bifocal, trifocal and extended-depth of focus intraocular lenses,” Clinical and Experimental Ophthalmology, vol. 45, p. 46, 2017.

[26] NCT, A Comparison of the Visual Performance of Trifocal versus Extended Depth of Focus Intraocular Lenses, https://clinicaltrialsgov/show/NCT03726606, 2018.

[27] NCT, A Comparison of FineVision Intraocular Lenses vs Symfony Intraocular Lenses, https://clinicaltrialsgov/show/NCT03974451, 2019.

[28] NCT, Non-inferiority Study Comparing MINI WELL READY® and FineVision® in Patients with Cataract Surgery, https://clinicaltrialsgov/show/NCT03060954%202017, 2017.

[29] C. Palomino-Bautista, R. Sánchez-Jean, D. Carmona-González, D. P. Piñero, and A. Molina-Martin, “Subjective and objective depth of field measures in pseudophakic eyes: comparison between extended depth of focus, trifocal and bifocal intraocular lenses,” International Ophthalmology, vol. 40, no. 2, pp. 351–359, 2020.

[30] B. Cochener, G. Boutillier, M. Lamard, and C. Aubeger-Zagnoli, “A comparative evaluation of a new generation of diffractive trifocal and extended depth of focus intraocular lenses,” Journal of Refractive Surgery, vol. 34, no. 8, pp. 507–514, 2018.

[31] G. Monaco, M. Gari, F. Di Censo, A. Poscia, G. Ruggi, and A. Scialdone, “Visual performance after bilateral implantation of 2 new presbyopia-correcting intraocular lenses: trifocal versus extended range of vision,” Journal of Cataract and Refractive Surgery, vol. 43, no. 6, pp. 737–747, 2017.

[32] V. S. C. Webers, N. J. C. Bauer, I. E. Y. Saelens et al., “Comparison of the intermediate distance of a trifocal IOL with an extended depth-of-focus IOL: results of a prospective randomized trial,” Journal of Cataract and Refractive Surgery, vol. 46, no. 2, pp. 193–203, 2020.

[33] M. A. Gil, C. Varon, G. Cardona, and J. A. Bull, “Visual acuity and defocus curves with six multifocal intraocular lenses,” International Ophthalmology, vol. 40, no. 2, pp. 393–401, 2020.

[34] R. Mencucci, E. Favuzza, O. Caporossi, A. Savastano, and S. Rizzo, “Comparative analysis of visual outcomes, reading skills, contrast sensitivity, and patient satisfaction with two models of trifocal diffractive intraocular lenses and an extended range of vision intraocular lens,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 256, no. 10, pp. 1913–1922, 2018.

[35] R. Ruiz-Mesa, A. Abengózar-Vela, and M. Ruiz-Santos, “A comparative study of the visual outcomes between a new trifocal and an extended depth of focus intraocular lens,” European Journal of Ophthalmology, vol. 28, no. 2, pp. 182–187, 2018.

[36] S. Escandon-Garcia, F. J. Ribeiro, C. McAlinden, A. Queiros, and J. M. González-Méjome, “Through-focus vision performance and light disturbances of 3 new intraocular lenses for presbyopia correction,” Journal of Ophthalmology, 2018.

[37] A. L. de Medeiros, F. Jones Saraiva, C. I. Igunsu et al., “Comparison of visual outcomes after bilateral implantation of two intraocular lenses with distinct diffractive optics,” Clinical Ophthalmology, vol. 13, pp. 1657–1663, 2019.

[38] B. Singh, S. Sharma, S. Dadia, N. Bharti, and S. Bharti, “Comparative evaluation of visual outcomes after bilateral implantation of a diffractive trifocal intraocular lens and an extended depth of focus intraocular lens,” Eye and Contact Lenses: Science and Clinical Practice, vol. 46, no. 5, 2019.

[39] L. Rodov, O. Reitblat, A. Levy, E. I. Assia, and G. Kleinmann, “Visual outcomes and patient satisfaction for trifocal, extended depth of focus and monofocal intraocular lenses,” Journal of Refractive Surgery, vol. 35, no. 7, pp. 434–440, 2019.

[40] M. Böhm, K. Petermann, E. Hemkeppler, and T. Kohnen, “Defocus curves of 4 presbyopia-correcting IOL designs: diffractive panfocal, diffractive trifocal, segmental refractive, and extended-depth-of-focus,” Journal of Cataract and Refractive Surgery, vol. 45, pp. 1625–1636, 2019.

[41] Y. Lin, X. Liang, J. Guo, X. Chen, and Z. Dong, “Comparison of clinical performance between trifocal IOL and EDOF IOL,” Investigative Ophthalmology & Visual Science, vol. 60, 2019.

[42] C. McAlinden, K. Pesudovs, and J. E. Moore, “The development of an instrument to measure quality of vision: the Quality of Vision (QoV) questionnaire,” Investigative Ophthalmology & Visual Science, vol. 51, no. 11, pp. 5537–5545, 2010.

[43] S. Ben Yaish, A. Zlotnik, I. Raveh, O. Yehezkeli, M. Belkin, and Z. Zalevsky, “Intraocular omni-focal lens with increased tolerance to decentration and astigmatism,” Journal of Refractive Surgery, vol. 26, pp. 71–76, 2010.

[44] D. Gatinel and J. Loiçq, “Clinically relevant optical properties of bifocal, trifocal, and extended depth of focus intraocular lenses,” Journal of Refractive Surgery, vol. 32, pp. 273–280, 2016.

[45] C. Canovas, A. Alarcon, J. Graver, H. A. Weeger, and P. A. Piers, “Preclinical evaluation of tolerance to astigmatism with an extended range of vision IOL,” Investigative Ophthalmology & Visual Science, vol. 57, p. 2, 2016.